Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
Ensysce Biosciences completed enrollment in Part 3 of the PF614-MPAR-102 clinical study, which evaluates the company's abuse-resistant opioid technology. The MPAR technology is designed to provide therapeutic opioid exposure at prescribed doses while automatically limiting release to protect against oral overdose. CEO Dr.
Key figures
- Drug Name
- PF614-MPAR
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.